IDEAYA's Darovasertib Combination Hits Primary Endpoint, Sets Stage for NDA Submission
Event summary
- IDEAYA's Phase 2/3 OptimUM-02 trial of darovasertib combination met primary endpoint, reducing risk of disease progression by 58% in HLA*A2-negative metastatic uveal melanoma.
- Company plans to submit NDA for darovasertib in H2 2026 under FDA's RTOR program for potential accelerated approval.
- IDEAYA reports $973 million in cash as of March 31, 2026, with runway guidance into 2030.
- Multiple clinical updates planned for H2 2026 across IDE849, IDE034, and IDE892 programs.
- IDEAYA to initiate registrational trial for IDE849 monotherapy in DLL3-positive solid tumors by year-end 2026.
The big picture
IDEAYA's positive trial results position it as a key player in precision oncology, particularly in uveal melanoma treatment. The company's strategic focus on multiple clinical programs and partnerships demonstrates its commitment to expanding its pipeline. With substantial cash reserves, IDEAYA is well-positioned to execute on its ambitious development plans, though it must carefully manage increasing operational costs as it progresses toward potential commercialization.
What we're watching
- Regulatory Pathway
- Whether IDEAYA can successfully navigate the RTOR program to achieve accelerated approval for darovasertib.
- Pipeline Execution
- The pace at which IDEAYA can deliver clinical updates across its diverse pipeline in H2 2026.
- Commercialization Readiness
- How IDEAYA prepares for potential commercialization of darovasertib while managing increased R&D expenses.
Related topics